Merck seeks improved hepatitis C treatment through buyout

Merck & Co., the second-biggest U.S. drugmaker, agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to expand its experimental pipeline for hepatitis C treatments.

Idenix holders will receive $24.50 a share in cash, Merck said in a statement today. The price is more than triple Idenix’s closing level on June 6 of $7.23. The premium is a record for healthcare deals larger than $100 million, according to data compiled by Bloomberg.

Buying the Cambridge, Massachusetts-based company will help Merck in the race to develop a daily, all-oral regimen that treats different strains of the viral infection and doesn’t include ribavirin, a standard treatment for hepatitis C that has serious side effects. In April, Merck said its once-a-day hepatitis C pill, which combined two drugs, stopped the virus in a mid-stage study in 98% of newly treated patients with few major side effects.

“We’ve been talking with Idenix for a long time, and have a long history in this field,” said Roger Perlmutter, who joined the Whitehouse Station, New Jersey-based company as president of Merck Research Laboratories in April, 2013.

Merck shares dropped less than 1% to $57.73 at 10:17 a.m. in New York time. Idenix shares more than tripled to $24.10.

Idenix came to Merck after another company approached it about a possible deal, Perlmutter said in a telephone interview today. Once that happened, Idenix started a sale, and “I’m delighted to say we won the process,” he said.
 

Gilead’s Sovaldi
 

Idenix’s lead drug, IDX21437, works similarly to Gilead Science Inc.’s Sovaldi, which won U.S. regulatory in December and costs $84,000 for a 12-week course of treatment. Prior to the development of Sovaldi, hepatitis C treatment entailed a regimen of two or more antiviral drugs with many side effects.

Merck is racing Gilead, Johnson & Johnson and Abbvie Inc. to establish a strong presence against a disease that affects an estimated 170 million people worldwide and carries a potential market of $20 billion a year.

“What we would like to do, insofar as it is possible, is cure them all,” Merck’s Perlmutter said in commenting on the number of people who carry the disease. To do that, Merck will need a three-drug combination pill that has few side effects and can be taken for a shorter period of time.

Idenix’s drug may offer that possibility when combined with Merck’s existing compounds, he said. IDX21437, which belongs to a class of drugs called nucleotide prodrug inhibitors, is Merck’s main interest, Perlmutter said. This class of treatments works by stopping the hepatitis C virus from replicating within the body.

Page 1 of 2 >>

Copyright 2014 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Comments
comments powered by Disqus